Geovax Labs Inc (GOVX) — Titan Protect Analysis

GOVX

Geovax Labs Inc

Healthcare · ·

$1.65

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$10M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.29

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-509.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+506% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Geovax Labs Inc

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell c

https://www.geovax.com

Country: United States Employees: 19 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.126

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0374

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.807

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-80.3%

Historical annualised return based on price data

Max Drawdown

-99.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$34.75

95% below the year high

52W Low

$0.96

71% above the year low

Avg Volume

4,829,685

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-13.82

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

79.91

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2,523.4%

Profit from core operations before interest and tax

Free Cash Flow

$-11,100,562

Negative — the business is spending more than it generates

Revenue (TTM)

$852,282

Total revenue over the last 12 months

Net Income

$-21,369,040

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$10.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go